Cargando…
Second-Generation Antimitotics in Cancer Clinical Trials
Mitosis represents a promising target to block cancer cell proliferation. Classical antimitotics, mainly microtubule-targeting agents (MTAs), such as taxanes and vinca alkaloids, are amongst the most successful anticancer drugs. By disrupting microtubules, they activate the spindle assembly checkpoi...
Autores principales: | Novais, Pedro, Silva, Patrícia M. A., Amorim, Isabel, Bousbaa, Hassan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309102/ https://www.ncbi.nlm.nih.gov/pubmed/34371703 http://dx.doi.org/10.3390/pharmaceutics13071011 |
Ejemplares similares
-
BP-M345, a New Diarylpentanoid with Promising Antimitotic Activity
por: Novais, Pedro, et al.
Publicado: (2021) -
Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel
por: Fonseca, Joana, et al.
Publicado: (2016) -
A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel
por: França, Fábio, et al.
Publicado: (2020) -
Discovery of a New Chalcone-Trimethoxycinnamide Hybrid with Antimitotic Effect: Design, Synthesis, and Structure—Activity Relationship Studies
por: Moreira, Joana, et al.
Publicado: (2023) -
Antimitotic drugs in the treatment of cancer
por: van Vuuren, Rustelle Janse, et al.
Publicado: (2015)